Adicet Bio Stock (NASDAQ:ACET)

Forecast Ownership Financials Chart

Previous Close

$0.78

52W Range

$0.45 - $1.70

50D Avg

$0.72

200D Avg

$0.89

Market Cap

$63.81M

Avg Vol (3M)

$502.24K

Beta

1.60

Div Yield

ACET Company Profile

Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

152

IPO Date

Jan 26, 2018

Website

ACET Performance

ACET Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	-	-	$24.99M
Operating Income	$-127.61M	$-152.04M	$-72.55M
Net Income	$-117.12M	$-142.66M	$-67.03M
EBITDA	$-127.61M	$-136.53M	$-64.70M
Basic EPS	$-1.33	$-3.31	$-1.63
Diluted EPS	$-1.33	$-3.31	$-1.63

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts

Q1 19Nov 10, 18 | 9:00 AM

Q4 18Sep 28, 18 | 9:00 AM

Q3 18May 04, 18 | 9:00 AM

Peer Comparison

Ticker	Company
ACIW	ACI Worldwide, Inc.
ACTG	Acacia Research Corporation
DSGN	Design Therapeutics, Inc.
ALXO	ALX Oncology Holdings Inc.
ADCT	ADC Therapeutics S.A.
AAON	AAON, Inc.
ABCB	Ameris Bancorp